ENGN Overview

enGene Holdings Inc. is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II study, which includes a cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (Cis). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. The Company is developing non-viral genetic medicines based on its DDX gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Wall Street analysts forecast ENGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENGN is23.88 USD with a low forecast of 10.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

enGene Holdings Inc revenue for the last quarter amounts to -31.18M USD, increased 17.18

enGene Holdings Inc. EPS for the last quarter amounts to -29056000.00 USD, increased 11.78

enGene Holdings Inc (ENGN) has 45 emplpoyees as of March 30 2026.

Today ENGN has the market capitalization of 426.72M USD.